• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears Stryker bone tumor ablation system

FDA clears Stryker bone tumor ablation system

September 20, 2022 By Sean Whooley

Marketing image of Stryker OptaBlate bone tumor ablation system
OptaBlate bone tumor ablation system [Image from Stryker]
Stryker (NYSE:SYK) announced today that the FDA granted 510(k) clearance for its OptaBlate bone tumor ablation system.

Kalamazoo, Michigan-based Stryker designed its OptaBlate system to allow physicians to easily customize their procedures. The system helps to reduce ablation time by three minutes.

The system features four probes and Stryker’s patented microinfusion technology. The company said adding it to its interventional spine portfolio expands its competencies in vertebral augmentation and radiofrequency ablation. It also completes its portfolio of treatment options for metastatic vertebral body fractures, Stryker said.

“Stryker’s new bone tumor ablation (BTA) system is a significant improvement on existing technology and builds on Stryker’s IVS portfolio,” said Dr. Anthony Brown, a vascular and interventional radiologist at Radiology Imaging Associates, Colorado. “There is no more deserving patient population for our attention and intervention; OptaBlate will change lives.”

More about Stryker’s OptaBlate

OptaBlate also offers a bipedicular approach that allows for the treatment of two vertebral body levels at once. It provides quicker, more consistent ablation.

The microinfusion technology keeps the zone hydrated, Stryker said. This reduces impedance errors and prevents charring.

Stryker plans to introduce OptaBlate at the North American Spine Society Annual Meeting next month in Chicago.

“Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs,” said Greg Siller, VP and GM, interventional spine business, Stryker. “OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning.”

Filed Under: 510(k), Business/Financial News, Featured, Food & Drug Administration (FDA), News Well, Orthopedics, Radiosurgery/Radiation therapy, Regulatory/Compliance, Spine Tagged With: FDA, Stryker

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy